Edition:
India

Granules India Ltd (GRAN.NS)

GRAN.NS on National Stock Exchange of India

82.15INR
9:43am IST
Change (% chg)

Rs-3.70 (-4.31%)
Prev Close
Rs85.85
Open
Rs85.00
Day's High
Rs85.00
Day's Low
Rs81.65
Volume
1,760,857
Avg. Vol
2,495,482
52-wk High
Rs150.00
52-wk Low
Rs71.55

Chart for

About

Granules India Limited is a pharmaceutical company with presence across the pharmaceutical manufacturing value chain, including active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediaries (PFIs) and finished dosages (FDs). The Company's business operations include three areas: core business, emerging... (more)

Overall

Beta: 1.10
Market Cap(Mil.): Rs30,908.89
Shares Outstanding(Mil.): 253.77
Dividend: 0.25
Yield (%): 0.74

Financials

  GRAN.NS Industry Sector
P/E (TTM): 16.72 30.95 32.74
EPS (TTM): 7.29 -- --
ROI: -- 14.84 14.38
ROE: -- 16.34 16.08

BRIEF-Granules India March-Qtr Consol Profit More Than Halves

* MARCH QUARTER CONSOL NET PROFIT 204.4 MILLION RUPEES VERSUS PROFIT 456.7 MILLION RUPEES YEAR AGO

24 May 2018

BRIEF-Granules India Gets ANDA Nod For Methocarbamol Tablet

* SAYS CO EXPECTS TO COMMERCIALIZE PRODUCT SHORTLY Source text - http://bit.ly/2jDfD0y Further company coverage:

08 May 2018

BRIEF-Granules India Gets One Form 483 Observation For Jeedimeetla Facility

* GAGILLAPUR, JEEDIMETLA FACILITIES COMPLETED U.S. FDA INSPECTION; NO 483 OBSERVATION FOR GAGILLAPUR; 1 OBSERVATION FOR JEEDIMEETLA Source text - http://bit.ly/2G5IloH Further company coverage:

26 Mar 2018

BRIEF-Granules India Says U.S. FDA Approves ANDA For Metformin Extended Release Tablets

* USFDA APPROVED ANDA FILED BY CO FOR METFORMIN EXTENDED RELEASE (ER) TABLETS 500 MG AND 750 MG

19 Mar 2018

BRIEF-Granules India Says U.S. FDA Issued EIR For Unit's Facility In Virginia

* SAYS U.S. FDA ISSUED EIR FOR GRANULES PHARMA FACILITY IN CHANTILLY, VIRGINIA

28 Feb 2018

BRIEF-Granules India Dec Qtr Consol Profit Falls

* DEC QUARTER CONSOL NET PROFIT 350.2 MILLION RUPEES VERSUS 390.6 MILLION RUPEES YEAR AGO

08 Feb 2018

Earnings vs. Estimates